FY2028 Earnings Forecast for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities researchers at Wedbush lifted their FY2028 earnings estimates for Disc Medicine in a research note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $7.04 per share for the year, up from their prior estimate of $6.85. Wedbush has a "Outperform" rating and a $83.00 price target on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.15) per share.

A number of other research analysts have also weighed in on IRON. Raymond James raised Disc Medicine from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, October 15th. HC Wainwright lifted their target price on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company assumed coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $85.80.

Disc Medicine Price Performance

NASDAQ IRON traded down $2.39 during trading on Thursday, reaching $60.67. 183,247 shares of the company's stock were exchanged, compared to its average volume of 355,568. The business has a 50 day moving average price of $50.81 and a 200-day moving average price of $44.64. The stock has a market capitalization of $1.80 billion, a P/E ratio of -15.79 and a beta of 0.60. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Hedge Funds Weigh In On Disc Medicine

Hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its position in shares of Disc Medicine by 50.6% during the 1st quarter. Swiss National Bank now owns 23,800 shares of the company's stock worth $1,482,000 after acquiring an additional 8,000 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Disc Medicine in the 1st quarter valued at $211,000. Bleakley Financial Group LLC raised its holdings in shares of Disc Medicine by 23.0% during the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company's stock worth $285,000 after buying an additional 856 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Disc Medicine during the 1st quarter worth $7,429,000. Finally, Vanguard Group Inc. boosted its stake in Disc Medicine by 2.4% in the first quarter. Vanguard Group Inc. now owns 782,751 shares of the company's stock valued at $48,734,000 after buying an additional 18,207 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Transactions at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the company's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 7,538 shares of company stock valued at $437,875. 4.24% of the stock is currently owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.